Skip to content

Tracking Inflammatory haematological markers in Patients with cancer of head and neck planned for concurrent chemo-radiation therapy

Evaluation of Inflammatory Biomarkers in Patients undergoing Chemoradiotherapy for Head and Neck Cancer: A Prospective Observational Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/05/111263
Enrollment
70
Registered
2026-05-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

Intervention1: Nil: Nil

Sponsors

JEEVANASPARSHA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients categorised by anatomical site according to the WHO Anatomical Classification of Head and Neck Tumors 5thEd, 2022. Histopathological confirmed cases only Scheduled for definitive Chemoradiotherapy (CRT) with radiation dose 70 Gy.

Exclusion criteria

Exclusion criteria: Systemic Co-morbidities: Cardiovascular diseases (arrhythmias, heart failure), Pulmonary diseases (COPD, asthma), Diabetes Mellitus, Liver disease, or Renal disease or any allergy. Clinical Factors: Concurrent non-HNC malignancies, substance use disorders (drugs), pregnancy, and mentally challenged individuals. Treatment Factors: Patients undergoing primary surgical treatment.

Design outcomes

Primary

MeasureTime frame
Haematological Predictors wherein these measures evaluate the systemic inflammatory and nutritional status of the patient at critical phases of therapyTimepoint: At Baseline before chemoradiotherapy, During chemoradiotherapy at 3rd week and 3rd month and post chemoradiotherapy at 6 month

Secondary

MeasureTime frame
Clinical Oral Changes wherein these measures assess functional & structural impact on oral cavity by standardised indicesTimepoint: At Baseline before chemoradiotherapy, During chemoradiotherapy at 3rd week and 3rd month and post chemoradiotherapy at 6 month

Countries

India

Contacts

Public ContactDr Shashikiran S

MCODS, Manipal.

shruthi.acharya@manipal.edu9900409822

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026